ROCHE HOLDINGS AG (RHHBY)

34.41
0.15 0.43
OTC
Prev Close 34.56
Open 34.73
Day Low/High 34.39 / 34.95
52 Wk Low/High 25.10 / 35.90
Volume 417.68K
Exchange OTC
Shares Outstanding 702.56B
Market Cap 195.59B
Div & Yield N.A. (N.A)

Latest News

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.

2 Biotech 'Busted IPOs' to Watch in 2018

2 Biotech 'Busted IPOs' to Watch in 2018

Are these names the next 'Ignytas'?

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

China Was Right to Walk Away From Failed U.S. Trade Talks

China Was Right to Walk Away From Failed U.S. Trade Talks

The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.

Global Investors Adjust to Rising Political Risks

Global Investors Adjust to Rising Political Risks

European stocks open lower Tuesday as global investors trim risky positions amid rising political tensions in the Gulf region and the ongoing turmoil in the White House.

What You Need to Know About Roche AG's Breast Cancer Drug Perjeta

What You Need to Know About Roche AG's Breast Cancer Drug Perjeta

Roche said patients treated with Perjeta combined with Herceptin and chemotherapy after surgery saw lower death risks and tumor return rates.

Roche CEO Bullish on U.S. Drug Market

Roche CEO Bullish on U.S. Drug Market

Roche shares gain after the company's CEO says he's 'fully dedicated' to the key U.S. market.

Closing Bell: Humana Slumps on Deal Worries; U.S. Stocks Mixed

Closing Bell: Humana Slumps on Deal Worries; U.S. Stocks Mixed

A sharp selloff in crude kept stocks mostly in the red, though optimism ahead of Friday's jobs reports kept losses to a minimum on Thursday.

3 Pharma Stocks to Heal Your Portfolio

Dividend yield is the determining factor in this strategy.

As the World Economic Forum Starts in Davos, Watch These 3 Swiss Stocks

The WEF host country has a lot to offer to investors.

Biotech Stocks at a Crossroad

Own them, or take something off the table?

The Action Is a Bit Worrisome

Things aren't bad, but the bulls need to go to work soon.

Five Things to Know Now: Pharma Mergers

Pharma mergers boost stocks.

Drugs IPOs Depend on Deals

Drugs IPOs Depend on Deals

Biotech IPOs that have relationships with established drug companies will do better than those going it alone.

Biotech's Next Big Thing: ASCO

Biotech's Next Big Thing: ASCO

TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.